A well-supplied UK & EU sector, led by PRINTING HOUSE LTD, most recent listing 11 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abrocitinib (ATC D11AH08) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will involve formal procurement proced
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication containing the active ingredients Tafluprost and Timolol (ATC S01ED70). This agreement is in accordance with § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical com
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent
AOK Bayern is seeking pharmaceutical companies to enter into non-exclusive discount agreements for the drug Airpiprazol in the form of depot injection suspension (ATC N05AX12). This is not a traditional open procedure but an open-house model, meaning contracts can be signed at any time until July 3,
This announcement is for the establishment of agreements with companies or consortia of companies for blood glucose test strips in accordance with Section 130a, Paragraph 8 of the Fifth Book of the Social Code (SGB V) for the state of North Rhine-Westphalia. Suppliers are invited to participate in a
This is not a standard open procedure but rather an open-house model! The form for the open procedure is used only because there is no form for the open-house model. Contracts made under the open-house model are not subject to procurement law due to the lack of selection decisions. The AOK Bayern in
The KKH (Kaufmännische Krankenkasse) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process allows all eligible and interested pharmaceutical companies or groups to
This contract opportunity involves establishing non-exclusive discount agreements for the drug Safinamide (ATC Code: N04BD03) under Section 130a (8) of the German Social Code (SGB V). The agreements will be made through an Open House model, allowing all interested pharmaceutical companies to partici
This announcement is for the establishment of contracts to supply medical dressings to the insured members of AOK NW, in accordance with § 31 SGB V, through an Open-House procedure. All qualified and interested service providers are invited to enter into this contract under uniform contractual condi
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredient Nilotinib (ATC: L01EA03) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
